Home / Therapeutic areas / Dermatology
Dermatology patient recruitment
No more dry patches in your dermatological patient pipeline, we have 20 years’ experience recruiting patients for dermatology clinical trials.
The dermatology trial landscape
3,100+
Dermatology trials actively recruiting
4,200+
study sites seeking patients
2,300+
Clinical trial sponsors
In a market with 3,100+ clinical trials targeting a limited pool of dermatology patients, Clariness is the right recruitment partner to ensure your study reaches the right patients ahead of your competition.
Reach & recruit the right patients, first.
Getting beneath the skin of dermatology patient recruitment barriers
Despite the global prevalence and impact of dermatological conditions, barriers to recruitment still remain, including:
- 42% of countries report poor access to dermatological services, leaving many undiagnosed and undertreated
- 9/10 patients in the EU report feeling embarrassed about their condition
- On average, 1 in 4 patients change their profession due to their dermatological condition
Half your population has no access to care or a diagnosis, those remaining don’t want to publicly address their condition. This, and many other factors, impact enrollment timelines. Luckily, Clariness has 20 years of dermatology experience and data to find and recruit your patients.
Proven results in dermatology recruitment
85+
Global dermatology studies supported
20+
Years of therapeutic expertise
1,200+
Patients randomized globally
Atopic dermatitis
Experience across 60+ atopic dermatitis studies, recruiting paediatric and adult patients.
Psoriasis
Recruited patients across 15+ psoriasis clinical trials with protocol-specific enrollment.
Acne
Supported patient recruitment (adolescent & adult patients) across 5+ acne studies
Spotlight: Clariness delivers 136% of patients for global atopic dermatitis study
Project overview:
- We supported a phase III atopic dermatitis study for a global leading biopharma
- Recruitment needed in 7 countries
- 85 sites onboarded, trained and supported in local language
Our results:
- 136% consented referrals vs. target
- 40% shorter delivery timeline
- 36% saved media budget
Placing recruitment solutions in the hands of your patients
We co-created an impactful self-screening technique for affected body surface area (BSA), one of the most required I/E criteria of dermatological study protocols.
The problem:
- Many patients struggle to adequately evaluate and describe their symptoms
- With miscalculated BSA will be rejected by sites, frustrating staff and patients
Our solution:
- We developed a unique self-screening process using a patient’s handprint ~1% BSA
- Our method works for both adults and children
This is just one of our approaches to improve patient referral quality for dermatology studies, reducing unnecessary site visits, and accelerating your time-to-market.
What do our patients say?
-
“Thus far I have received prompt access to clinical trials in my area and within my scope of interest. Website and links are simple and easy to navigate.”
Kamau BenjaminPatient -
“The trial had my 7-year-old see an excellent dermatologist, and the treatment is clearing up her spots!”
Patient with a child suffering from vitiligo in Mexico
Dermatology FAQs
Why is patient education important in dermatology clinical trial recruitment?
Many people living with skin conditions experience stigma, fear of judgment, or uncertainty about participating in clinical research. To address this issue, our creatives team develops empathetic, patient-centric communications, imagery, and educational materials that resonate with dermatology patients and those they involve in their participation decision process, helping build trust, improve understanding, and encourage informed participation and engagement throughout the recruitment journey.
Why do dermatology clinical trials experience high screen failure rates?
Many dermatology studies rely on patient-reported symptoms and treatment history, which may not always align with clinically verified eligibility criteria, resulting in unnecessary site burden and longer recruitment timelines. Clariness reduced these challenges through innovative protocol-specific screening techniques and continuous site support, helping confirm disease severity, treatment history, and patient eligibility before referral.
How does Clariness verify patient eligibility for dermatology clinical trials?
Assessing prior treatment adequacy and disease severity can be challenging for others, particularly for protocols with strict I/E criteria. For Clariness, we have two layers of patient-centric pre-screening, combined with video calling, image uploads, self-screening techniques, MRR, and a wealth of other tactics, we deliver best-in-class referral quality.
How many dermatology indications does Clariness support?
Clariness supports recruitment across a wide range of dermatology indications, including atopic dermatitis, psoriasis, acne, actinic keratosis, alopecia areata, chronic wounds, onychomycosis, pyoderma gangrenosum, rosacea, scars, stretch marks, skin pigment disorder, systemic lupus, SLE, Uremic pruritus, Urticaria, and many others.
Can dermatology clinical trial recruitment be completed ahead of schedule?
Yes, targeted recruitment across social media and digital channels, combined with two-step online & phone screening to validate key I/E criteria, and continuous campaign optimization based on performance insights can significantly accelerate patient referrals. In a global phase III atopic dermatitis study, Clariness exceeded its consented referral target by 136%, completed recruitment with 40% ahead of schedule, and reduced media spend by 36%.
Related insights
-
Rescue recruitment case studies
See how delayed studies achieved faster enrollment and exceeded recruitment targets.14 Aug 2025Case study -
Psoriasis case study
Learn how we’ve supported a sponsor with patient recruitment for psoriasis study.02 Aug 2023Case study -
Atopic dermatitis case study
Learn how we’ve supported sponsors with their patient recruitment for atopic dermatitis studies.18 Apr 2023Case study